Clearstead Advisors, LLC Igm Biosciences, Inc. Transaction History
Clearstead Advisors, LLC
- $6.94 Billion
- Q2 2025
A detailed history of Clearstead Advisors, LLC transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 61 shares of IGMS stock, worth $77. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61Holding current value
$77% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding IGMS
# of Institutions
68Shares Held
15.1MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.1MShares$5.2 Million0.05% of portfolio
-
Siren, L.L.C. New York, NY3.26MShares$4.13 Million0.19% of portfolio
-
Redmile Group, LLC San Francisco, CA2.95MShares$3.75 Million0.4% of portfolio
-
Black Rock Inc. New York, NY883KShares$1.12 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY855KShares$1.09 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $36.8M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...